Archemix inks IP deal with Ribomic; Cytori to raise $17M;

> Archemix says it will earn a $6 million upfront payment from Ribomic in exchange for a license to certain IP property rights to develop aptamers against multiple targets. Archemix is also eligible to receive more than $200 million in milestone payments. Archemix release

> Cytori Therapeutics says it plans to raise approximately $17 million from a private placement financing led by Olympus Corporation with participation from select institutional investors. Cytori release

> Centocor says the FDA has extended the review timeline for the Biologic License Application for ustekinumab by three months to December 2008. Centocor release

> An independent data monitoring group says that Affymax should continue its late-stage trials of Hematide. Story

> Chromos Molecular Systems has entered into an agreement with Calyx Bio-Ventures and Modatech Systems agreeing to affect a plan of arrangement. Chromos release

> Sound Pharmaceuticals has received FDA notification that it may proceed with its Phase II study to prevent chemotherapy induced hearing loss. Release

> Biogen and Elan--along with proponents of preemption--were dealt a setback today as a federal judge declined to transfer a case from Massachusetts to a federal court in Iowa. Report

> An Irish man's death has prompted calls for doctors to suspend Lipitor use when treating patients with certain antibiotics. Lipitor report

> If the government says cancer drugs aren't worth the cost, then what? Ask drugmakers to cut their prices. Report

> We all know the challenges pharma faces: generic competition, patent expirations, sluggish pipelines, pricing pressures. Or do we? A new study suggests that the huge volume of uninsured and underinsured people may be seriously cutting into drugmakers' sales. Report

> Prices have ballooned by 100 percent or more for a growing number of drugs, according to a new study. Report

And Finally... Indonesian health officials are working to determine if 13 newly hospitalized patients in the country were infected with bird flu. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.